PMID- 11143285
OWN - NLM
STAT- MEDLINE
DCOM- 20010201
LR  - 20111117
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 141
IP  - 47
DP  - 2000 Nov 19
TI  - [Molecular biology follow-up of interferon therapy in patients with chronic 
      myeloid leukemia].
PG  - 2527-33
AB  - In a prospective survey clinical haematological and molecular biological data of 
      31 patients with chronic myelogenous leukaemia (chronic phase, CML) observed in 
      their haematological outpatient department were analyzed. During 1996 and 1999 a 
      regular follow-up of the Philadelphia chromosome level in treated patients was 
      performed with molecular biological techniques, i.e. with reverse transcription 
      polymerase chain reaction (RT-PCR) and with fluorescence in situ hybridization 
      (FISH) methods. During the follow-up period of 33 months from the 31 patients 
      with CML (16 males, 15 females) 25 ones were treated with human recombinant 
      interferon-alpha (IFN), however, six others were getting only hydroxyurea (HU). 
      During this period in three patients allogen bone marrow transplantation was 
      performed and seven ones expired (six out of them of blastic crisis). The quality 
      of therapeutic response at cytogenetical level was determined by decrease of the 
      bcr-abl level due to the treatment (non-responders, major, minor and complete 
      cytogenetic remission groups). In nine patients (five from the IFN-group, four 
      from the HU-group) achieved no cytogenetic therapeutic response (non-responders, 
      29%). However, in 13 patients a minor (bcr-abl range of 60-30%), and in nine 
      patients a maior/complete (bcr-abl of 30-10%) cytogenetic response (42% and 29%, 
      respectively) were detected. Moreover, the quality of cytogenetic response 
      correlated with the haematological remission. The maior/complete cytogenetic 
      response was durable in eigth patients. The improvement of the overall survival 
      of patients with CML, the postpone of the fatal accelerated-blastic phase could 
      be expected only from the early introduced, in individually adjusted and given in 
      maximally tolerated dosage of interferon (3-5 million UI/m2/day). The qualitative 
      (RT-PCR) and quantitative (FISH) detections of the Philadelphia chromosome are 
      reliably reproducible up-to-date molecular biological methods getting relevant 
      results, which could be very helpful in the planning, monitoring, in setting of 
      optimal dosage of the interferon therapy of patients with CML, in addition in the 
      judgement of the effectiveness of the therapy, in the reduction of adverse 
      effects, as well as in forecasting of the cytogenetic progression.
FAU - Ivanyi, J L
AU  - Ivanyi JL
AD  - Vas Megyei Markusovszky Korhaz Szombathely, Hematologiai Osztaly.
FAU - Marton, E
AU  - Marton E
FAU - Kereskai, L
AU  - Kereskai L
FAU - Kiss, Z
AU  - Kiss Z
FAU - Pajor, L
AU  - Pajor L
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - Kronikus myeloid leukemias betegek interferon-kezelesenek kovetese molekularis 
      biologiai modszerekkel.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon Type I)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, abl/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interferon Type I/*therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/*genetics
MH  - Male
MH  - *Philadelphia Chromosome
MH  - Recombinant Proteins
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Translocation, Genetic
MH  - Treatment Outcome
EDAT- 2001/01/06 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/06 11:00
PHST- 2001/01/06 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/06 11:00 [entrez]
PST - ppublish
SO  - Orv Hetil. 2000 Nov 19;141(47):2527-33.